Menu Search
Equities

Evolus Inc

EOLS:NMQ

Evolus Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)13.68
  • Today's Change-0.61 / -4.27%
  • Shares traded1.28m
  • 1 Year change+56.52%
  • Beta1.2807
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Evolus Inc grew revenues 35.98% from 148.62m to 202.09m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -74.41m to -61.69m.
Gross margin69.94%
Net profit margin-22.33%
Operating margin-16.40%
Return on assets-27.90%
Return on equity--
Return on investment-38.48%
More ▼

Cash flow in USDView more

In 2023, Evolus Inc increased its cash reserves by 16.53%, or 8.92m. Cash Flow from Financing totalled 44.64m or 22.09% of revenues. In addition the company used 34.01m for operations while cash used for investing totalled 1.63m.
Cash flow per share-0.8294
Price/Cash flow per share--
Book value per share0.0931
Tangible book value per share-0.9787
More ▼

Balance sheet in USDView more

Evolus Inc has a Debt to Total Capital ratio of 95.37%.
Current ratio2.47
Quick ratio2.23
Total debt/total equity20.58
Total debt/total capital0.9537
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.